 |
The triad of erectile dysfunction, hypogonadism and metabolic syndrome |
|
Although traditionally people believed that testosterone is a risk factor for cardiovascular disease in men, recently more evidence emerged that higher testosterone levels are associated with a more favourable risk effect on the risk of cardiovascular disease. Shabsigh et al. (2008) identified the relationship among erectile dysfunction, hypogonadism and metabolic syndrome.
|
Read more...  |
 |
 |
|
|
Effect of difluoromethylornithine on decreasing prostate size and polyamines |
|
Prostate cancer is a major health issue, and prevention of prostate cancer and its progression will yield benefits for men. Difluoromethylornithine (DFMO) is an antiproliferative agent, inhibiting ornithine decarboxylase, the first enzyme in the polyamine pathway, and has been studied as a therapeutic and chemopreventive agent. The prostate has high levels of tissue polyamines and has shown sensitivity to DFMO both in vitro and in vivo. Simoneau et al.
(2008) evaluated the effect of DFMO on prostate cancer.
|
| Read more... |
|
|
Hedgehog signalling in androgen independent prostate cancer |
|
Androgen-deprivation therapy effectively shrinks hormone-naive prostate cancer, both in the prostate and at sites of distant metastasis. However, prolonged androgen deprivation generally results in relapse and androgen-independent tumour growth, which is inevitably fatal. The molecular events that enable prostate cancer cells to proliferate in reduced androgen conditions are poorly understood. Shaw et al. (2008) studied the role of Hedgehog signalling in androgen-independent prostate cancer (AIPC).
|
| Read more... |
|
|
Endoglin (CD105) as a potential urinary marker for prostate cancer detection
|
|
Dr. Kazutoshi Fujita et al. presented the findings of their study on endoglin (CD105) as a potential urinary marker for prostate cancer (PCa) detection at the First Genitourinary Cancers Symposium held under the auspices of the American Society of Clinical Oncology (ASCO) in San Francisco, USA.
|
| Read more... |
|
|
Smart bombs against cancer: Translating theory into therapy |
|
Targeted treatment for prostate cancer with “Smart Bombs” was the message delivered by Dr. John Isaacs from The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in his State-of-the-art lecture at the 23rd EAU annual congress in Milan, Italy.
|
| Read more... |
|
